NasdaqGM:CGEN

Stock Analysis Report

Executive Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe.

Snowflake

Fundamentals

Flawless balance sheet with concerning outlook.

Risks

  • Compugen is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Compugen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.9%

NasdaqGM:CGEN

-5.2%

US Life Sciences

0.6%

US Market


1 Year Return

9.2%

NasdaqGM:CGEN

22.2%

US Life Sciences

4.1%

US Market

CGEN underperformed the Life Sciences industry which returned 24.1% over the past year.

CGEN outperformed the Market in United States of America which returned 4.7% over the past year.


Share holder returns

CGENIndustryMarket
7 Day0.9%-5.2%0.6%
30 Day4.7%0.05%3.8%
90 Day7.9%6.1%2.8%
1 Year9.2%9.2%22.4%22.2%6.4%4.1%
3 Year-44.7%-44.7%82.7%81.2%47.0%37.3%
5 Year-59.4%-59.4%117.2%106.7%60.3%42.5%

Price Volatility Vs. Market

How volatile is Compugen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Compugen undervalued based on future cash flows and its price relative to the stock market?

6.4x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Compugen to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Compugen to establish if it is available at substantial discount.


Price Based on Earnings

Compugen is loss making, we can't compare its value to the US Life Sciences industry average.

Compugen is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Compugen, we can't assess if its growth is good value.


Price Based on Value of Assets

Compugen is overvalued based on assets compared to the US Life Sciences industry average.


Next Steps

Future Growth

How is Compugen expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-7.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Compugen's revenue is expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).

Compugen is not considered high growth as it is expected to be loss making for the next 1-3 years.

Compugen's revenue growth is expected to exceed the United States of America market average.

Unable to compare Compugen's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Compugen's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Compugen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Compugen performed over the past 5 years?

-17.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Compugen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Compugen's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Compugen's 1-year growth to the US Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Compugen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Compugen has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Compugen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Compugen's financial position?


Financial Position Analysis

Compugen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Compugen's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Compugen has no debt.

Compugen has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Compugen has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Compugen has sufficient cash runway for 2.8 years based on current free cash flow.

Compugen has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -10.7% each year.


Next Steps

Dividend

What is Compugen's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Compugen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Compugen's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Compugen has not reported any payouts.

Unable to verify if Compugen's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Compugen has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Compugen's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Anat Cohen-Dayag (52yo)

9.3yrs

Tenure

US$854,003

Compensation

Dr. Anat Cohen-Dayag, Ph.D., has been the Chief Executive Officer at Compugen Ltd. since March 2010 and serves as its President since June 2009. Dr. Cohen-Dayag served as Vice President of Research & Devel ...


CEO Compensation Analysis

Anat's remuneration is about average for companies of similar size in United States of America.

Anat's compensation has increased whilst company is loss making.


Management Age and Tenure

2.6yrs

Average Tenure

51.5yo

Average Age

The tenure for the Compugen management team is about average.


Board Age and Tenure

5.9yrs

Average Tenure

62yo

Average Age

The tenure for the Compugen board of directors is about average.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Kirk Christoffersen (50yo)

    Senior Vice President of Corporate & Business Development

    • Tenure: 2.6yrs
    • Compensation: $639.39k
  • Ari Krashin (46yo)

    Chief Financial & Operating Officer

    • Tenure: 4.8yrs
    • Compensation: $575.74k
  • Martin Gerstel (78yo)

    Senior Advisor

    • Tenure: 1.4yrs
  • Henry Adewoye

    Chief Medical Officer

    • Tenure: 1.3yrs
    • Compensation: $612.73k
  • Anat Cohen-Dayag (52yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: $854.00k
  • John Hunter (56yo)

    Chief Scientific Officer

    • Tenure: 0.8yrs
    • Compensation: $602.79k
  • Elana Holzman

    Director of Investor Relations & Corporate Communications

  • Zurit Levine (51yo)

    Senior Vice President of Technology Innovation

    • Compensation: $356.02k
  • Donna Gershowitz (55yo)

    General Counsel

  • Dorit Amitay (51yo)

    Vice President of Human Resources

    • Tenure: 12.5yrs

Board Members

  • Anat Cohen-Dayag (52yo)

    CEO, President & Director

    • Tenure: 5.4yrs
    • Compensation: $854.00k
  • Arie Ovadia (71yo)

    External Director

    • Tenure: 12.0yrs
  • Sandy Zweifach (63yo)

    Director

    • Tenure: 1.1yrs
  • Drew Pardoll

    Chairman of Scientific Advisory Board

  • Paul Sekhri (61yo)

    Chairman

    • Tenure: 1.8yrs
  • Iain McInnes

    Member of Scientific Advisory Board

    • Tenure: 5.9yrs
  • Charles Drake

    Member of Scientific Advisory Board

    • Tenure: 5.9yrs
  • Toni Ribas

    Member of Scientific Advisory Board

    • Tenure: 5.9yrs
  • Kinneret Savitzky (52yo)

    Director

    • Tenure: 1.1yrs
  • Yair Aharonowitz (78yo)

    External Director

    • Tenure: 12.0yrs

Company Information

Compugen Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Compugen Ltd.
  • Ticker: CGEN
  • Exchange: NasdaqGM
  • Founded: 1993
  • Industry: life sciences tools and services
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$212.653m
  • Shares outstanding: 59.90m
  • Website: Click here

Number of Employees


Location

  • Compugen Ltd.
  • Building D
  • 26 Harokmim Street
  • Holon
  • 5885849
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGENNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDAug 2000
CGENTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSAug 2000
CW9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2000

Biography

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company’s the ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/16 23:47
End of Day Share Price2019/07/16 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.